Get the Stockscreener App
266.61
1.21%
-3.2194
Natera Inc stock is traded at $266.61, with a volume of 76,446.
It is down -1.21% in the last 24 hours and up +17.72% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$269.83
Open:
$265.4
24h Volume:
76,446
Relative Volume:
0.05
Market Cap:
$38.18B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-162.45
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
-1.25%
1M Performance:
+17.72%
6M Performance:
+15.27%
1Y Performance:
+85.92%
1-Day Range:
$262.00
$268.36
1-Week Range:
$261.63
$282.00
52-Week Range:
$131.81
$288.04
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
266.61 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
535.96 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.91 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.82 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
134.00 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio - Business Wire
The Bull Case For Natera (NTRA) Could Change Following New Signatera JAMA Oncology Evidence On MRD-Guided Chemotherapy - simplywall.st
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks - Yahoo Finance
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves. - The Motley Fool
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
Form 4 Natera Inc For: 15 July By Investing.com - Investing.com Nigeria
Natera (NTRA) co-founder sells 3,150 shares under Rule 10b5-1 plan - Stock Titan
Natera co-founder Sheena Jonathan sells $836,898 in stock - Investing.com
Rowan Emma Chapman (NASDAQ: NTRA) files Form 144 to sell shares - Stock Titan
Form 144 Natera For: 15 July By Investing.com - Investing.com Canada
NTRA (NASDAQ: NTRA) holder plans sale of 1,500 common shares - Stock Titan
NATERA INC : TD COWEN RAISES TARGET PRICE TO $325 FROM $280 - Moomoo
NTRA Maintained by Canaccord Genuity -- Price Target Raised to $330 - GuruFocus
Enterprise value to EBITDA forward of Natera, Inc. – BX:NTRA - TradingView
Form 144 Natera For: 13 July By Investing.com - Investing.com Canada
[144] Natera, Inc. SEC Filing - Stock Titan
Enterprise value to EBITDA forward of Natera, Inc. – XETR:45E - TradingView
Did EU Class C Status for Signatera Reshape Natera’s (NTRA) Long-Term Diagnostics Strategy? - Yahoo Finance
What's Driving Natera's Recent Stock Action and Insider Selling - Kavout | AI
Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification? - simplywall.st
Natera (NTRA) Secures EU Certification, Is The Upside Already Priced In? - Yahoo Finance
Why Natera (NTRA) Stock Is Down Today - Quiver Quantitative
Natera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgery - Yahoo Finance
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers - Yahoo Finance
Natera (NTRA) Stock Still Looks Expensive After A Very Large Run - Yahoo Finance
NTRA Maintained by Morgan Stanley -- Price Target Raised to $310 - GuruFocus
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
Natera, Inc. Stock 12‑Month Price Target Raised to $272.19, Implies 1% Downside - TradingView
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers - 01net
How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative - simplywall.st
Natera’s Signatera receives EU IVDR certification for MRD testing By Investing.com - Investing.com Nigeria
Natera’s Signatera receives EU IVDR certification for MRD testing - Investing.com
Natera Receives EU IVDR Certification for Signatera - Moomoo
Natera (NTRA) Achieves Significant Milestone with Signatera IVDR Certification - GuruFocus
Natera's Insider Selling Spree: A Red Flag Amidst Robust Growth - Kavout | AI
Natera executive chairman Matthew Rabinowitz sells $280,000 in shares By Investing.com - Investing.com Nigeria
Natera executive chairman Matthew Rabinowitz sells $280,000 in shares - Investing.com
(NTRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Form 4 Natera Inc For: 8 July By Investing.com - Investing.com Nigeria
Natera (NTRA) executive chair’s spouse sells 1,000 shares in pre‑planned trade - Stock Titan
Form 4 Natera Inc For: 6 July By Investing.com - Investing.com India
Natera president Solomon Moshkevich sells $818,710 in stock - Investing.com UK
Natera chief legal officer Daniel Rabinowitz sells $4.57m stock - Investing.com
Natera chief legal officer Daniel Rabinowitz sells $4.57m stock By Investing.com - Investing.com Australia
Natera | 4: Statement of changes in beneficial ownership of securities-Director Rubin Eric H - Moomoo
Natera president Solomon Moshkevich sells $818,710 in stock By Investing.com - Investing.com Australia
Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 trading plan - Stock Titan
Natera (NTRA) legal chief sells 16,800 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NATERA For: 6 July By Investing.com - Investing.com South Africa
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):